SPRB vs. EGRX, NVCT, ADAG, PDSB, IMUX, CLRB, VTGN, DMAC, CYTT, and PMVP
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Eagle Pharmaceuticals (EGRX), Nuvectis Pharma (NVCT), Adagene (ADAG), PDS Biotechnology (PDSB), Immunic (IMUX), Cellectar Biosciences (CLRB), Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMAC), Cyteir Therapeutics (CYTT), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
Spruce Biosciences (NASDAQ:SPRB) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
In the previous week, Spruce Biosciences and Spruce Biosciences both had 3 articles in the media. Eagle Pharmaceuticals' average media sentiment score of 0.82 beat Spruce Biosciences' score of 0.72 indicating that Eagle Pharmaceuticals is being referred to more favorably in the news media.
Eagle Pharmaceuticals has a net margin of 0.00% compared to Spruce Biosciences' net margin of -461.67%. Eagle Pharmaceuticals' return on equity of 0.00% beat Spruce Biosciences' return on equity.
Eagle Pharmaceuticals has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Spruce Biosciences has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
Spruce Biosciences currently has a consensus target price of $5.67, suggesting a potential upside of 664.63%. Eagle Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 389.91%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Eagle Pharmaceuticals.
91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Eagle Pharmaceuticals received 374 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 70.43% of users gave Eagle Pharmaceuticals an outperform vote while only 63.33% of users gave Spruce Biosciences an outperform vote.
Summary
Eagle Pharmaceuticals beats Spruce Biosciences on 11 of the 17 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
